As MCL patients with HRD defined by high MIPI-c or high p53 expression/TP53 alteration had a dismal clinical course of the disease, we recommend to incorporate these factors in routine diagnostic practice as suggested by the WHO 5th edition and the International Consensus Classification (ICC) to identify patients with need for novel therapeutic strategies [32, 33]. This evidence concerns the gene TP53 and hypoparathyroidism-retardation-dysmorphism syndrome.